.Merck & Co.'s TIGIT plan has experienced an additional misfortune. Months after shuttering a sta...
.After a year determined by pipe cuts, the shift of its chief executive officer and cutbacks, Exscie...
.Cullinan Rehab was actually blown away enough with Port BioMed's bispecific immune reactor that it ...
.In this full week's episode of "The Best Line," our experts are actually diving into Intense Biotec...
.The confetti is still soaring coming from Eli Lilly's gathering celebrating the approval of Alzheim...
.Accept to this week's Chutes & Ladders, our roundup of substantial management hirings, firings a...
.Following an unsatisfactory showing for Lykos Therapies' MDMA candidate for trauma at a latest FDA ...
.AN2 Therapeutics is reconsidering its organization in action to uninspired midphase records, promis...
.Merck & Co. is actually paying for $700 million in advance to test Amgen in a blood cancer cells...
.Along With Gilead Sciences almost an FDA selection for its liver disease medication seladelpar, the...